Alpha 2.0
Login Register
» Authors » Heather M A Prince

Heather M A Prince

Explore the profile of Heather M A Prince including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 17
Citations 457
Followers 0
Related Specialties
Infectious Diseases
Microbiology
Chemistry
Top 10 Co-Authors
Angela D M Kashuba
Craig Sykes
Kristine B Patterson
Mackenzie L Cottrell
Evan S Dellon
Julie B Dumond
Nicole White
Myron S Cohen
Julie A E Nelson
Jessica L Adams
Published In
J Acquir Immune Defic Syndr
Antivir Ther
Anal Chem
J Antimicrob Chemother
Sci Transl Med
Affiliations
Soon will be listed here.
Recent Articles
11.
Analysis of Antiretrovirals in Single Hair Strands for Evaluation of Drug Adherence with Infrared-Matrix-Assisted Laser Desorption Electrospray Ionization Mass Spectrometry Imaging
Rosen E, Thompson C, Bokhart M, Prince H, Sykes C, Muddiman D, et al.
Anal Chem . 2015 Dec; 88(2):1336-44. PMID: 26688545
Adherence to a drug regimen can be a strong predictor of health outcomes, and validated measures of adherence are necessary at all stages of therapy from drug development to prescription....
12.
Effect of HIV infection and menopause status on raltegravir pharmacokinetics in the blood and genital tract
Cottrell M, Patterson K, Prince H, Jones A, White N, Wang R, et al.
Antivir Ther . 2015 Jun; 20(8):795-803. PMID: 26040011
Background: This study describes first dose and steady state pharmacokinetics of raltegravir (RAL) in cervicovaginal fluid (CVF) and blood plasma (BP). Methods: Three cohorts of women were enrolled sequentially in...
13.
Models for predicting effective HIV chemoprevention in women
Nicol M, Emerson C, Prince H, Nelson J, Fedoriw Y, Sykes C, et al.
J Acquir Immune Defic Syndr . 2014 Dec; 68(4):369-76. PMID: 25501616
Objective: Model systems that rapidly identify tissue drug concentrations protective of HIV infection could streamline the development of chemoprevention strategies. Tissue models are promising, but limited concentration targets exist, and...
14.
Expression of six drug transporters in vaginal, cervical, and colorectal tissues: Implications for drug disposition in HIV prevention
Nicol M, Fedoriw Y, Mathews M, Prince H, Patterson K, Geller E, et al.
J Clin Pharmacol . 2013 Dec; 54(5):574-83. PMID: 24343710
Effective antiretroviral (ARV)-based HIV prevention strategies require optimizing drug exposure in mucosal tissues; yet factors influencing mucosal tissue disposition remain unknown. We hypothesized drug transporter expression in vaginal, cervical, and...
15.
Dolutegravir pharmacokinetics in the genital tract and colorectum of HIV-negative men after single and multiple dosing
Greener B, Patterson K, Prince H, Sykes C, Adams J, Dumond J, et al.
J Acquir Immune Defic Syndr . 2013 Aug; 64(1):39-44. PMID: 23945251
Objectives: To describe first-dose and steady state pharmacokinetics (PKs) of dolutegravir (DTG) in blood plasma (BP), seminal fluid (SF), colorectal tissue (RT), and rectal mucosal fluid (RF) of healthy HIV-negative...
16.
Single and multiple dose pharmacokinetics of dolutegravir in the genital tract of HIV-negative women
Adams J, Patterson K, Prince H, Sykes C, Greener B, Dumond J, et al.
Antivir Ther . 2013 Aug; 18(8):1005-13. PMID: 23899439
Background: Antiretrovirals that achieve adequate concentrations in anatomical sites of transmission are of interest for HIV prevention. A Phase I open-label pharmacokinetic (PK) study was performed to describe first dose...
17.
Tenofovir diphosphate and emtricitabine triphosphate concentrations in blood cells compared with isolated peripheral blood mononuclear cells: a new measure of antiretroviral adherence?
Adams J, Sykes C, Menezes P, Prince H, Patterson K, Fransen K, et al.
J Acquir Immune Defic Syndr . 2012 Nov; 62(3):260-6. PMID: 23111578
Background: The active metabolites of tenofovir (TFV) and emtricitabine (FTC) in peripheral blood mononuclear cells (PBMCs) have been used as markers of long-term antiretroviral (ARV) adherence. However, the process of...